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Conformational dynamics of a G protein–coupled 
receptor helix 8 in lipid membranes
Patricia M. Dijkman1*†, Juan C. Muñoz-García1†‡, Steven R. Lavington1, Patricia Suemy Kumagai1,2,  
Rosana I. dos Reis1§, Daniel Yin1, Phillip J. Stansfeld3,4, Antonio José Costa-Filho5, Anthony Watts1||
G protein–coupled receptors (GPCRs) are the largest and pharmaceutically most important class of membrane 
proteins encoded in the human genome, characterized by a seven-transmembrane helix architecture and a 
C-terminal amphipathic helix 8 (H8). In a minority of GPCR structures solved to date, H8 either is absent or adopts 
an unusual conformation. The controversial existence of H8 of the class A GPCR neurotensin receptor 1 (NTS1) has 
been examined here for the nonthermostabilized receptor in a functionally supporting membrane environment 
using electron paramagnetic resonance, molecular dynamics simulations, and circular dichroism. Lipid-protein 
interactions with phosphatidylserine and phosphatidylethanolamine lipids, in particular, stabilize the residues 374 to 
390 of NTS1 into forming a helix. Furthermore, introduction of a helix-breaking proline residue in H8 elicited 
an increase in ß-arrestin–NTS1 interactions observed in pull-down assays, suggesting that the structure and/or 
dynamics of H8 might play an important role in GPCR signaling.
INTRODUCTION
G protein–coupled receptors (GPCRs) are of considerable biological 
and pharmacological significance, since they account for ~1% of 
human genome-encoded proteins and are implicated in a variety 
of biological processes and pathologies (1). In recent years, GPCR 
structural biology has undergone rapid progress as a result of ad-
vances in protein engineering, the use of lipidic cubic phases and 
x-ray free-electron lasers for crystallography, and most recently, 
developments in cryo-electron microscopy (cryo-EM) (2), resulting 
in structures for 57 unique receptors published to date. In all cases, 
GPCRs are characterized by a seven-transmembrane helix archi-
tecture, with the majority of structures displaying an additional 
structural element, helix 8 (H8). H8 is an amphipathic  helix 
that follows the conserved NPxxY motif on transmembrane helix 
7 (TM7). Sequence alignment of class A GPCRs reveals a semi-
conserved motif F(R/K)xx(F/L)xxx(L/F) for H8 (fig. S1). Physio-
logical studies have shown H8 to be important for surface expression 
of GPCRs, for receptor trafficking, and for G protein activation and 
specificity thereof (3–7). Moreover, biophysical studies of the  opioid 
receptor (8, 9) and rhodopsin (10–12) suggest that the conformational 
dynamics of H8 are involved in GPCR (pre-)activation and interaction 
with arrestin (12).
Given the potential functional significance of H8, it is noteworthy 
that in a minority of structures, H8 either is absent or adopts an 
unusual conformation (fig. S1 and table S1); of the 367 structures of 
class A GPCRs published to date, all but 30 (~8%), representing 17 
(~30%) of the 57 unique class A GPCRs for which structures have 
been published, show a helical H8. In some cases, this can be ratio-
nalized by the lack of sequence determinants, but for several recep-
tors, specifically, the adenosine A1 receptor (A1R), the angiotensin 
II type 1 and type 2 receptors (AT1R and AT2R, respectively), the 
CC chemokine receptor type 2, the D4 dopamine receptor, the puri-
nergic P2Y12 receptor (P2Y12R), and the rat neurotensin receptor 1 
(NTS1), one or more of the reported structures lack H8 despite the 
presence of an intact H8 motif (fig. S1). The rat NTS1 is of particular 
interest, since eight crystal structures have been published to date, 
demonstrating distinct conformations of H8 (table S2) (13–16). In 
all cases, thermostabilizing mutations and C-terminal and/or intra-
cellular loop 3 (IC3) truncations were necessary for crystallization of 
NTS1, with four of the crystal constructs also containing T4-lysozyme 
(T4L) insertions (table S2) (13, 15, 16). Crystallographic studies of 
NTS1 using constructs in which functionally impairing mutations 
were reverted back to wild-type (WT) (15), or with alternative thermo-
stabilizing mutations lacking a T4L insertion, which showed improved 
functionality (14), did show the presence of H8.
Here, we sought to determine the conformation adopted by the 
H8 residues in an NTS1 construct having the full-length C terminus 
and no thermostabilizing mutations, as well as the influence of the 
lipid environment and receptor activation state on this conformation. 
A combination of continuous-wave electron paramagnetic resonance 
(CW-EPR), circular dichroism (CD), and molecular dynamics (MD) 
demonstrate that NTS1 has a dynamic H8 that is dependent on 
lipid-protein interactions for its helicity. Furthermore, agonist bind-
ing to the receptor induces (subtle) rearrangements of the helix, and 
disruption of helical structure by a proline mutation affects NTS1- 
arrestin binding in human embryonic kidney (HEK) 293T cells. 
Together, these results emphasize the importance of lipids in H8 
structure and the dynamic nature of H8 in NTS1.
1Biomembrane Structure Unit, Department of Biochemistry, University of Oxford, 
South Parks Road, Oxford OX1 3QU, UK. 2Instituto de Física de São Carlos, Universidade 
de São Paulo, Av. Trabalhador São-Carlense 400, C.P. 369, São Carlos SP 13560-970, 
Brazil. 3Department of Biochemistry, University of Oxford, South Parks Road, Oxford 
OX1 3QU, UK. 4School of Life Sciences & Department of Chemistry, University of 
Warwick, Coventry CV4 7AL, UK. 5Departamento de Física, Faculdade de Filosofia, 
Ciências e Letras de Ribeirão Preto, Universidade de São Paulo, Av. Bandeirantes 
3900, Ribeirão Preto SP 14040-901, Brazil.
*Present address: Max Planck Institute for Biophysics, Max-von-Laue-Straße 3, 60438 
Frankfurt am Main, Germany; Institute of Neuropathology, University Medical Center 
Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany; Cluster of Excellence 
“Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells” 
(MBExC), University of Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
†These authors contributed equally to this work.
‡Present address: School of Pharmacy, University of East Anglia, Norwich Research 
Park, Norwich NR4 7TJ, UK.
§Present address: National Physical Laboratory, Hampton Road, Teddington TW11 
0LW, UK.
||Corresponding author. Email: anthony.watts@bioch.ox.ac.uk
Copyright © 2020 
The Authors, some 
rights reserved; 
exclusive licensee 
American Association 
for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
NonCommercial 
License 4.0 (CC BY-NC).
 o
n
 August 16, 2020
http://advances.sciencem
ag.org/
D
ow
nloaded from
 
Dijkman et al., Sci. Adv. 2020; 6 : eaav8207     14 August 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 13
RESULTS
CW-EPR reveals helical periodicity for H8
CW-EPR was used to probe the secondary structure and conforma-
tional dynamics of H8 in NTS1 reconstituted into a lipid bilayer and 
lacking any thermostabilizing mutations that were previously required 
for crystallization (table S2) (13–16). Specifically, cysteine mutations 
for site-directed spin labeling with 2,2,5,5-tetramethylpyrroline-1- 
oxyl-3-methyl)methanethiosulfonate (MTSL) (R1) were introduced 
into a background mutant of NTS1 (C-NTS1) in which native 
accessible cysteines were mutated to serine or alanine residues 
(C172S3.55, C278SIC3, C332S6.59, C386SC-term, and C388AC-term). The 
background mutant shows the same affinity for agonist as WT 
receptor [dissociation constant (Kd) ≤ 2 nM) (17), single-cysteine 
mutants thereof were previously shown to be able to bind Gi1 in a 
guanosine 5′-O-(3′-thiotriphosphate)–dependent manner (17), and 
all single-cysteine mutants used here showed salt-sensitive binding 
to a ligand affinity column, as expected for functional NTS1, al-
though signaling competence was not tested. CW-EPR spectra were 
recorded at 295 and 170 K (figs. S2 and S3, respectively) for NTS1 
sequentially spin-labeled at the C-terminal residues 374 to 393 
reconstituted in brain polar lipid (BPL) extract liposomes. NTS1 
has previously been shown to be functional within this lipid en-
vironment (18).
All spectra were complex, containing multiple dynamic compo-
nents; a more (c ≈ 30 to 200 ns) and a less (c ≈ 2 ns) motionally 
restricted component, labeled “i” and “m,” respectively (fig. S2), can 
be distinguished. These two components could arise from different 
conformational states of the receptor or from spin label rotamers 
with different interactions with their environment, resulting in dif-
ferent amplitude of motion, rate of motion, or both (19). Changes 
in the intensity of these components reflect changes in the popula-
tion of the corresponding protein states or spin label rotamers. The 
outer splittings (2Azz′) reflect the mobility of the more restricted 
component “i,” while the width of the central resonance line (H0) 
is only somewhat biased by the more mobile spectral component 
“m,” and is a good overall measure of spin label mobility (fig. S2) 
(10, 19).
As the mobility of the spin label, and thus H0, is dependent on 
its local environment, the secondary structure of a sequence can be 
assessed from the periodicity in this mobility parameter (10). Plot-
ting the inverse of the central linewidth against residue number 
shows that H0−1, for part of the probed stretch, follows a sine func-
tion, indicative of helical periodicity (Fig. 1A). To determine the 
length of the helix, sine functions were fit to all possible residue 
stretches between 4 and 20 residues long, and fitting results were 
ranked according to the residual sum of squares. The periodicity in 
H0−1 for apo receptor was most consistent with two helical stretches 
kinked around residues F380-L381 (Fig. 1A). The data in the pres-
ence of saturating concentrations of agonist, neurotensin (NT; Fig. 1B), 
were consistent with an uninterrupted helix, and in both cases, the 
periodicity was approximately 3.6 residues (Fig. 1, A and B, dotted 
lines). No clear periodicity could be discerned beyond residue W391, 
which follows helix-breaking residues P389 and G390, suggesting 
that the rest of the probed C terminus lacks regular structure. Com-
pared to the apo state, the presence of agonist elicited the largest 
changes in the local dynamics of the residues flanking the putative 
helix kink (380 to 382) as gauged by the observed differences in 
H0−1 and the relative contributions of the more and less motionally 
restricted spectral components (Fig. 1, B to F, and fig. S2). Addition 
of NT resulted in either an increase in local dynamics (increase in 
H0−1, residue 381; Fig. 1, C and E) or a decrease (residues 380 and 
382; Fig. 1, C, D, and F). The observation of opposite effects on spin 
label mobility for alternating residues (378 to 383; Fig. 1C) may re-
flect a local reorientation of the helix relative to the membrane, 
allowing the formation of an uninterrupted helix. An increase in H0−1 
in the presence of NT compared to apo receptor was observed for 
most label positions on the C-terminal half of H8 (from 383 onward) 
and the unstructured C-terminal stretch beyond H8, suggesting 
an overall increase in spin label mobility in the presence of agonist 
(Fig. 1C), although the effect of agonist on the spectra was modest 
(fig. S2).
H8 secondary structure is stabilized by membranes
To assess the influence of the membrane on the secondary structure of 
H8, a peptide corresponding to H8 (S373-C388) was studied by far- 
ultraviolet (UV) CD in aqueous buffer, in detergent, and in liposomal 
suspensions of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) or the more native BPL. In the absence of detergent or lipid 
(black line; Fig. 2), the CD spectrum is characteristic of an unstruc-
tured peptide (8 ± 1% helical; fig. S4A), showing a strong negative 
signal around 200 nm. However, in the presence of lipids (red and 
gray lines; Fig. 2) or detergents (fig. S4A), the peptide shows a higher 
propensity to adopt a helical secondary structure (~29 to 65% helical; 
fig. S4A). Although it has to be noted that the very low lipid-to-protein 
ratio (5:1, mol:mol) used to minimize scattering in the far-UV re-
gion of the spectrum means that the spectra are likely to be subject 
to flattening, affecting the reliability of detailed spectral analysis, the 
differences between the spectra in the presence and absence of lipid 
are a clear indication of the stabilizing effect of lipid membranes on 
the secondary structure of this amphipathic helix.
The type of lipid used influenced the CD spectra of the NTS1 H8 
peptide. The blue shift of ~2 nm in the zero crossing ( = 0) ob-
served in the presence of POPC compared to BPL (Fig. 2) is indicative 
of reduced -helical content (29 ± 2% and 34 ± 1% followed from 
spectral analysis for POPC and BPL, respectively). Furthermore, 
while the shape of the CD spectrum of the peptide in the presence 
of POPC was similar to that of the peptide in detergent, the pres-
ence of BPL resulted in a more pronounced CD signal at ~225 nm 
(Fig. 2 and fig. S4A). These results suggest that other types of 
lipid present in BPL besides phosphatidylcholine (PC) lipids, e.g., 
phosphatidyl ethanolamine (PE) or phosphatidylserine (PS) lipids, 
constituting ~33 and ~19% of BPL, respectively, could have stabi-
lizing interactions with H8.
H8 interacts predominantly with lipid headgroups
To determine the depth of H8 penetration into lipid bilayers, the 
effect of the S373-C388 H8 peptide on acyl chain order of POPC model 
membranes was examined using EPR and spin-labeled PC lipids 
[1-palmitoyl-2-stearoyl-(5/12/14-doxyl)-sn-glycero-3-phosphocholine 
(DOXYL-PC)]. Large unilamellar vesicles (LUVs; 100 nm) were 
formed, with a DOXYL-PC spin label specifically installed in either 
the outer or inner leaflet of the vesicle (20). EPR spectra were re-
corded in the absence and presence of H8 peptide (fig. S4B), and the 
apparent order parameters Sapp, derived from the hyperfine splittings 
of the spectra (21), were calculated (Table 1). The greatest increase 
of Sapp, indicating decreased motional freedom, was observed in the 
peptide-accessible outer leaflet of the model membrane compared 
to the peptide-inaccessible inner leaflet. The greatest increase (+15%) 
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was observed with lipids labeled with DOXYL in the 5-position of 
the carbon chain, closest to the external headgroup region. A more 
modest increase was observed at the 12- and 14-positions of the 
outer leaflet (+4.0% and 3.7%, respectively). Barely any ordering 
was observed at the 5-, 12-, and 14-positions of spin-labeled lipids 
residing in the inner leaflet (0.9%, 1.2% and 0.5%, respectively). 
These data suggest that the S373-C388 H8 peptide interacts with 
zwitterionic model membranes primarily via surface interactions, 
with minimal insertion of the peptide into the hydrophobic core of 
the bilayer, consistent with its predicted amphipathic nature. The 
asymmetry of the order parameters across the membrane suggests 
that, in LUVs of this lipid composition, H8 does not insert as a 
transmembrane peptide. The absence of a substantial ordering of 
the inner leaflet also suggests that the peptide does not cross the 
membrane to interact with the inner surface of the vesicle.
MD reveals specific lipid-protein interactions stabilizing H8
The role of lipid-protein interactions in the stability of H8 second-
ary structure was studied in more detail by atomistic MD (AT-MD) 
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Fig. 1. CW-EPR analysis of H8 periodicity. Sequential single cysteine mutants of NTS1 were labeled with MTSL, generating the R1 side chain. EPR spectra were recorded 
at 295 K for residues along the C-terminal stretch after TM7, encompassing the putative H8 (see fig. S2). H0−1 determined from spectra of NTS1 (A) in the absence (apo, 
black squares) or (B) presence (+NT, red triangles) of agonist recorded at 295 K is shown here, plotted against residue number. H0−1 data points for apo receptor (black 
circles) are also shown in (B) for comparison. The dotted gray and red sinusoids have a period of 3.6 residues. (C) The difference in the mobility parameter H0−1 observed 
between the spectra recorded in the presence (H0−1NT) and absence of NT (H0−1apo) is shown for each residue position. A positive value reflects an increase in local 
dynamics of the spin label in the presence of agonist with respect to the apo receptor. Error bars represent the SEM (n = 2); note that lack of an error bar means that both 
measurements gave the same value. (D to F) Averaged spectra (n = 2) recorded in the absence (black line) and presence of agonist (NT, red lines) and difference spectra 
[(+NT) - (apo), gray line] are shown for three label positions showing the largest spectral changes in the presence of agonist compared to apo: (D) F380R1, (E) L381R1, and 
(F) S382R1. The spectra are multicomponent, containing a more and less motionally restricted component, labeled “i” and “m,” respectively.
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Fig. 2. CD analysis of influence of membrane mimetic on H8 secondary struc-
ture. The molar CD () of a peptide (0.1 mg/ml) corresponding to a short NTS1 
C-terminal stretch (S373-C388) including the H8 sequence was measured in saline 
buffer in the absence of lipids (black line) and in the presence of POPC (gray line) or 
BPL extract (red line) liposomes at a 5:1 lipid-to-peptide molar ratio. Smoothed 
data (fat line) are plotted on top of the raw data.
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simulations of peptides corresponding to H8, specifically, a short 
H8 peptide (H8p; residues A374-A385) and a longer peptide (eH8p, 
A374-H393), as well as of the whole receptor. Simulations were 
run in both a POPC and a BPL-mimicking membrane bilayer con-
sisting of cholesterol, POPC, 1-palmitoyl-2-oleoyl-sn-glycero- 3-
phosphoethanolamine (POPE), and 1-palmitoyl-2-oleoyl-sn-glycero-
3-phospho-l-serine (POPS) (see the Materials and Methods) for the 
H8 peptides and the receptor. Analogous simulations in explicit 
water in the absence of lipids were also run for the H8 peptides. The 
secondary structure of H8 was tracked along the 200-ns simulations, 
and any lipid-protein interactions with H8 were investigated. The 
length of the AT-MD trajectories is within the same dynamic range 
of anisotropy averaging of the nitroxide spin label motion in CW-
EPR (nanosecond) (21) and therefore suitable for comparison with 
the EPR experiments.
While both H8 peptides (H8p and eH8p) appeared to be fully 
unstructured in water, in the presence of a BPL-like membrane, 
predominantly, - and -helical conformations were observed along 
the trajectories (fig. S5, A and B). The initial -helical structure of 
H8p and eH8p was completely lost by the end of the trajectories in 
the presence of only POPC, suggesting that interaction with POPS, 
POPE, and/or cholesterol can stabilize H8, in agreement with the 
higher -helical content observed by CD in the presence of BPL 
compared to POPC (Fig. 2 and fig. S4A). For both the shorter H8p 
and the longer eH8p, the helical structure of the N-terminal half of 
the peptide (376 to 380) appeared more stable than the C-terminal 
half (>381), with the latter only showing helical tendency during part 
of the trajectories. The NTS1 model based on the 4BUO structure 
(14) with thermostabilizing mutations reverted back to the corre-
sponding WT residues showed an  helix for the A374-L384 frag-
ment throughout the 200-ns simulation when embedded in a BPL-like 
membrane, while the presence of POPC alone only partially stabilized 
the helix (A374-L381/S382; fig. S5C). During the AT-MD trajectory 
of the NTS1 model in a BPL-like membrane, H8 remains parallel to 
the membrane plane with its hydrophobic (residues F3768.50, F3808.54, 
and L3848.58) and hydrophilic (residues N3758.49, Q3788.52, and S3828.56) 
side membrane buried and solvent-exposed or at the solvent-membrane 
interface, respectively (fig. S5D). Also, the packing of H8 with TM1 
and TM7 does not deviate substantially from the crystal structure 
(fig. S5E) (14). In POPC, H8 adopted a different orientation with 
respect to the TM helix bundle, kinking away further from TM1, 
when compared to both the 4BUO crystal structure (14) and the 
AT-MD simulation in a BPL-like membrane (fig. S5E). The limited 
stability of NTS1 in POPC compared to BPL is also reflected in the 
backbone fluctuations observed during the AT-MD simulations, 
where average backbone root mean square deviations (RMSDs) of 
1.9 ± 0.8 Å and 0.9 ± 0.2 Å were found for H8 and 4.2 ± 0.9 Å and 
3.5 ± 0.3 Å for the NTS1 model overall within a POPC and a BPL-
like membrane, respectively. Again, these observations suggest that 
interactions of H8 with POPE, POPS, and/or cholesterol play a role 
in maintaining its secondary structure.
To provide more insight into the conformational dynamics of 
H8 in a BPL-like lipid membrane and the effects of ligand binding, 
additional triplicate simulations of the receptor in the apo and the 
agonist-bound state were run. As before, an  helix was observed for 
the apo receptor throughout the 200-ns simulation for the A374- L384 
fragment, and the average backbone RMSDs of H8 and NTS1 overall 
(0.9 ± 0.2 Å and 3.6 ± 0.3 Å, respectively) were also in agreement 
with the previous simulation (0.9 ± 0.2 Å and 3.5 ± 0.3 Å, respec-
tively). In the NT-bound state, a marked increase in mobility was 
seen for H8 (residues A374-C386) and TM7-H8 (I364-C386) com-
pared to the apo state receptor. While the backbone RMSD of the 
TM helices shows only a very modest increase from 2.1 ± 0.2 Å in 
the apo state to 2.3 ± 0.2 Å in the NT-bound state, the RMSDs of H8 
and TM7-H8 increased from 0.9 ± 0.2 Å and 0.9 ± 0.2 Å to 1.8 ± 0.3 
Å and 2.3 ± 0.3 Å, respectively (fig. S6). In addition, H8 loses part of 
its helical structure, in particular, at the N-terminal end (residues 
A374-N375/F376), in the simulations of the agonist-bound receptor 
(fig. S7A); the number of contacts observed between Y7.53 (Y369) 
and F8.50 (F376) is strongly reduced compared to the apo state 
from 28 ± 9 to 2 ± 5 contacts; and the angle between TM7 and H8 
changes drastically (Fig. 3A). NT makes extensive contacts with a 
cascade of mostly aromatic residues and two arginine residues at 
the extracellular (EC) end of TM6 and TM7. While the EC end of 
TM6 moves toward the receptor core (from residue W3216.48 onward), 
that of TM7 moves outward (fig. S7B), possibly contributing to the 
observed increase in RMSD in TM7 and H8 of NT-bound NTS1 
compared to the apo receptor (fig. S6). Reorientation of Y7.53 to-
ward N7.49 and D2.50 as observed in various active-state structures 
of GPCRs has been proposed to be a main part of the activation 
mechanism (22) and was indeed observed in one of the three simu-
lations of NT-bound NTS1, but not in the other two, where Y3697.53 
was either found in a hydrophobic pocket made up of L1062.43, V3096.36, 
and V3136.40 or made - contacts with F3808.54 (Fig. 3B). To probe 
the importance of Y7.53-F8.50 stacking for the stability of H8, trip-
licate simulations of a Y7.53A mutant of NTS1 in the apo state in 
BPL-like membranes were run. The Y7.53A mutation lead to a more 
modest increase in mobility of H8 and TM7 compared to WT 
receptor than that elicited by the presence of agonist; the backbone 
RMSDs of H8 and TM7-H8 only increased to 1.1 ± 0.3 Å and 
1.3 ± 0.2 Å, respectively, compared to 0.9 ± 0.2 Å and 0.9 ± 0.2 Å 
for WT apo NTS1 and 1.8 ± 0.3 Å and 2.3 ± 0.3 Å for NT-bound 
NTS1 (fig. S6). While the number of contacts between Y7.53 and 
F8.50 during the course of the simulation was reduced (21 ± 7 
Table 1. Effect of H8 peptide on spin-labeled lipids. Apparent order parameters Sapp were calculated for lipids spin labeled at different positions and in 
different leaflets from hyperfine splitting. 
S
Sapp inner leaflet labeled
% Change
Sapp outer leaflet labeled
% Change
With H8 Without H8 With H8 Without H8
5-PCSL 0.542 0.537 +0.9 0.517 0.594 +15.0
12-PCSL 0.189 0.187 +1.2 0.186 0.179 +4.0
14-PCSL 0.136 0.135 +0.5 0.126 0.121 +3.7
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versus 28 ± 9 for WT, a likely reduction with a Bayesian t test 
probability of 0.88), it is still significantly higher than the number 
of contacts observed for the NT-bound receptor (only 2 ± 5). The 
angle between TM7 and H8 did increase during the simulations 
of the Y7.53A mutant and fluctuated more strongly than during the 
simulations of the WT apo receptor (Fig. 3A). Thus, the Y7.53-F8.50 
interaction does appear to have a stabilizing role on H8, but its loss 
in the agonist-bound state is not the sole cause of the strong effect 
of agonist on H8 conformational dynamics observed in the AT-MD 
simulations.
To investigate the role of particular lipid species in the stability 
of H8, given the observed enhanced stability of H8 in BPL com-
pared to POPC membranes, we looked at the number of close 
lipid-protein contacts (≤3.5 Å) during the simulations, normalizing 
for the total number of contacts observed and correcting for the 
relative proportions of each lipid species in the bilayer (Fig. 4). 
In the apo state, while the whole receptor showed some preference 
for contacts with POPS over the other phospholipids (fig. S8A), at 
H8, POPE and, to a lesser extent, POPS were particularly enriched 
(Fig. 4A and fig. S8B), with most contacts observed at R3778.49 and 
C3868.60 (Fig. 4B and fig. S8C); hydrogen bonds and electrostatic 
interactions were observed between the side chains and the lipid 
headgroup, phosphate, and/or glycerol moieties (Fig. 4C). These 
interactions with C3868.60 may play a role in preventing the unfold-
ing of the C-terminal end of H8, since in the POPC-only mem-
brane, a shorter H8 was observed. While the Y7.53A mutation did 
not have a significant effect on the observed lipid-protein contacts 
compared to the apo WT receptor, in the agonist-bound state, the 
number of contacts with POPS increased strongly at H8 (Fig. 4A 
and fig. 8D), but not significantly for the receptor overall (fig. S8, A 
and D); interactions with the POPS headgroup were seen mainly at 
R3778.49 and C3868.60 (Fig. 4C and fig. S8C). The POPS lipid tails 
also interacted with a number of hydrophobic H8 residues (F3808.54, 
L3818.55, and L3848.58) and R3778.49 (fig. S8C), possibly due to the 
change in angle between TM7 and H8 exposing these residues more 
to the surrounding lipid membrane.
H8 in NTS1 signaling
To gain insight into the role of H8 in NTS1 at the cellular level, WT 
NTS1, NTS1 with a helix-breaking proline substitution at position 
V3798.53 (NTS1-V379P), and NTS1 with a conservative mutation at 
the same position (NTS1-V379L) were expressed in HEK293T cells, 
and the recruitment of ß-arrestin-1 was investigated (Fig. 5, A and B). 
Following NT stimulation, the amount of ß-arrestin-1 binding to 
the receptor was probed using pull-down assays. Our results show a 
significantly higher amount of -arrestin-1 bound to the NTS1-V379P 
compared with the WT NTS1 receptor (Fig. 5A), while no significant 
difference was found for NTS1-V379L (Fig. 5B). While it appeared 
that the V379P8.53 mutation might also affect extracellular signal–
regulated kinases 1 and 2 (ERK1/2) phosphorylation (Fig. 5C), 
further supporting that H8 could be involved in NTS1-arrestin in-
teractions, the differences in phosphorylation levels between the 
mutant and WT NTS1 were not statistically significant.
DISCUSSION
Mounting evidence suggests that, in addition to its importance in 
GPCR biogenesis and trafficking (3–6), H8 may play a role in early 
GPCR activation (8, 9, 12) and biased signaling through the arrestin 
pathway (6, 9, 12). Notably, a subset of all class A GPCR structures 
solved to date (30 of 367) did not have a canonical H8 perpen-
dicular to the TM bundle following TM7. Sequence alignment of 
all crystallized GPCRs shows that for some of these receptors, this 
may be due to the absence of certain conserved residues of the H8 
F8.50(R/K)8.51xx(F/L)8.54xxx(L/F)8.58 motif (table S1); the sequences 
of the leukotriene 4 BLT1 receptor, the lysophosphatic acid 6 receptor, 
and free fatty acid 1 receptor (FFA1R) deviate substantially from the 
canonical sequence, with FFA1R even having a proline residue at 
Fig. 3. TM7-H8 angle in MD simulations. (A) The angle between TM7 and H8 calculated between the vector formed by the C atoms of Y360-N370 (on TM7) and the 
vector formed by the C atoms of F376-F380 (on H8) is shown here for all MD simulations. The average angle during the simulations of apo WT NTS1 is shown as a dark 
gray line in each panel, while the light gray lines indicate the average RMSD of ±1 SD. (B) The cytosolic end of TM7 (blue) and H8 (pink) are shown for the final frame of 
one simulation (run 2) of the apo receptor (Apo) and all three simulations of the NT-bound receptor (+NT). While Y7.53 interacts with F8.50 during the simulations of the 
apo receptor, in the presence of NT, Y7.53 interacts with N7.49 and D2.50 (run 1), or the cytosolic end of TM7 unwinds (runs 2 and 3, red arrow) without Y7.53 interacting 
with N7.49 and D2.50.
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position 8.50. However, other receptors, such as NTS1, have been 
crystallized without a structured eighth helix despite showing a (near) 
canonical H8 sequence. Conversely, receptors with similarly deviating 
sequences, e.g., the lysophosphatidic acid receptor 1 (MSxxFxxxL), 
the C5a1 receptor (SLxxNxxxE), or the sphingosine-1-phosphate 
receptor 1 (MRxxFxxxM), lacking the most conserved Phe, have only 
been crystallized with a structured H8 (table S1), suggesting that the 
stability of the helix cannot be rationalized by sequence determi-
nants alone.
Although most of the GPCR structures for which H8 was found 
to be unstructured were solved using constructs containing an IC3 
insertion, and a destabilizing effect of the insertion cannot be ex-
cluded, there seems to be no clear correlation between the presence 
of an IC3 fusion and the absence of H8. Many other GPCRs have 
been crystallized with a structured H8 despite the presence of an 
IC3 insertion; not all structures of receptors that have been found to 
lack a structured H8 were solved using constructs containing an IC3 
insertion (e.g., for AT1R, AT2R, and A1R, an N-terminal fusion 
protein was used instead); and in some cases, the same or similar 
constructs containing an IC3 insertion have resulted in structures 
with and without a helical H8 (e.g., for P2Y12R-bRIL and the various 
thermostabilized forms of NTS1-T4L).
Thus far, 10 receptor subtypes have been crystallized, both with 
and without a helical H8 (fig. S1). For NTS1, this discrepancy 
between crystal structures was suggested to reflect the relative low 
stability of H8 (14) or differences in activation state of the receptor 
(15, 23), which were produced using different thermostabilized 
constructs showing varying degrees of G protein activation (table S2) 
(13–16). Here, using CW-EPR spectroscopy, we could demonstrate 
the presence of a helical H8, for a nonthermostabilized, non–C- 
terminally truncated NTS1 construct reconstituted in lipid bilayers. 
Helical periodicity was observed stretching from residue A3748.48 up 
to G3908.64/W3918.65, both for the apo receptor and in the presence 
of agonist. It has to be noted that the Pro-to-Cys mutation and spin 
labeling required for the EPR measurements at position 389 may 
have negated any helix-disrupting effect of the native proline, thus 
extending H8 beyond its native length. However, the observed change 
in amplitude of H0−1 for the flanking residues G3908.64 and W3918.65 
relative to L3878.61 and C3888.62, determined in the presence of the 
native Pro, follows the trend expected for continuation of the helical 
periodicity over that stretch of the sequence, suggesting H8 ends 
shortly after the helix-breaking Pro8.63-Gly8.64 residues. In the ab-
sence of ligand, the periodicity in the EPR mobility parameters was 
best fit with a discontinuous helix, with a kink around residues 
F3808.54/L3818.55. The structured stretch of H8 in NTS1 crystal struc-
tures varied from N3758.47-F3808.54 at the shortest [Protein Data Bank 
(PDB) ID 4XES] to A3748.48-L3878.61 at the longest (PDB ID 4BV0, 
chain B; table S2). Notably, the end of the shortest resolved struc-
tured H8 coincides with the location of the putative helix kink ob-
served in our EPR experiments.
Previous fluorescence, double electron-electron resonance (DEER), 
and nuclear magnetic resonance (NMR) spectroscopy studies have 
Fig. 4. Lipid-protein interactions observed in MD. (A) The number of lipid-protein contacts (≤3.5 Å) per lipid species observed during AT-MD simulations of NTS1 in 
a BPL-like bilayer was normalized by the total number of interactions during each simulation run and weighted by the percentage of each lipid type found in the mixed 
bilayer. Results are shown for simulations of apo WT NTS1 (Apo), NT-bound WT NTS1 (+NT), and apo mutant NTS1 where Tyr369 is mutated to Ala (Y7.53A). Averages of 
three simulation runs for each condition for the timeframe in equilibrium (20 to 200 ns) are shown with error bars representing the SD. Contacts are shown (A) for H8 as 
a whole (residues A374-C386) and (B) for the individual H8 residues. Contacts for the whole receptor, a breakdown of the contacts into contacts with the lipid tails and 
lipid headgroups, and statistical analysis are shown in fig. S8. (C) Final frame of the AT-MD simulation of apo NTS1 in a BPL-like bilayer, showing NTS1 (gray cartoon) and 
lipids surrounding H8 (highlighted in pink). POPS (dark blue sticks) and POPE (cyan sticks) lipids are observed clustered around R3778.51 (magenta) and the C-terminal 
C3868.60 (magenta) throughout the AT-MD simulations. CHOL, cholesterol.
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suggested that agonist binding alone can trigger changes in the local 
dynamics of TM7/H8 in a number of different GPCR subtypes 
(8, 9, 11, 24, 25), independent of the well-described outward move-
ment of TM6 upon GPCR activation (8, 25), suggesting that conforma-
tional changes in TM7, H8, and IC1 may precede TM6 movement 
(8, 25). While the presence of ligand did not affect the overall struc-
ture of H8 of NTS1, as gauged here by EPR, it did appear to induce 
some local dynamic effects. The largest changes were observed for 
the residues flanking the putative helix kink (F3808.54 to S3828.56; 
Fig. 1 and fig. S2), suggestive of a local rearrangement of H8 possibly 
resulting in an uninterrupted helix, as implied by the H0−1 period-
icity in the presence of agonist. Notably, these changes occur close 
to the highly conserved F8.50 residue (F376 in NTS1). F8.50 is pro-
posed to interact with the similarly conserved Y7.53 of the NPxxY 
motif on TM7 in the inactive state of class A GPCRs. It is thought 
that the interactions between Y7.53 and F8.50 are broken upon ac-
tivation (22), which may contribute to the changes in H8 dynamics 
upon activation (8, 9, 11, 24, 25); a slight inward movement of the 
cytosolic end of TM7 relative to its position in the inactive state has 
been observed in crystal structures of the agonist-bound (inter-
mediate) active state of several GPCRs (22), confirming earlier ob-
servations by DEER spectroscopy of rhodopsin activation (11). This 
repositioning of TM7 and concomitant repositioning of the side chain 
of Y7.53 toward the transmembrane core precluding its interaction 
with F8.50 has been suggested to lead to steric stabilization of TM6 in 
its active pose (22). For example, in the various “active-like” agonist- 
bound rat NTS1 crystal structures, Y7.53 packs against TM2, TM3, 
and TM6 and does not interact with F8.50 (13, 15). Notably, different 
conformations of the NPxxY motif were also reported in a recent 
cryo-EM study of a human NTS1 (hNTS1) construct in two Gi1- 
coupled states of the receptor (26): a canonical and a noncanonical 
state. While the G protein exhibited a very different binding pose 
in the noncanonical state, being rotated by about 45° compared to 
the canonical state, the overall structure of hNTS1 was very similar 
in both states, with the exception of TM7. In the canonical hNTS1 
state, Y7.53 was found in the transmembrane core packing against 
TM6, as observed in the active-like rat NTS1 structures (13, 15), dis-
torting the NPxxY region of TM7, while in the noncanonical hNTS1 
state, Y7.53 adopts a more “inactive-like” conformation similar to 
the 4BUO NTS1 structure, packing against L1052.43 (L106 in rat NTS1 
numbering), suggesting that it represents an activation intermediate. 
Notably, H8 is structured in both hNTS1-Gi1 structures but shorter 
in the more active-like canonical state (N8.49-F8.54 versus S8.47-C8.60 
in the noncanonical state). In our AT-MD simulations of NT-bound 
NTS1, the number of contacts between Y7.53 and F8.50 was reduced 
significantly, and TM7 and H8 were more flexible compared to the 
apo receptor. Eliminating the - stacking interaction by mutation 
of Y7.53 to Ala had a more modest effect on the flexibility of H8 
(fig. S6) and the angle between TM7 and H8 (Fig. 3); indeed, Y7.53A 
still showed CH- interactions with F8.50. Thus, it is possible that 
a change in the interaction between Y7.53 and F8.50 upon ligand 
binding contributes to a locally more dynamic H8 without affecting 
its secondary structure, in combination with other destabilizing ef-
fects of ligand binding on TM7 (fig. S7). The EPR spectra showed a 
modest increase in H0−1 in the presence of NT compared to apo 
receptor for most label positions on the C-terminal half of H8 (from 
383 onward) and the unstructured C-terminal stretch beyond H8 
(Fig. 1C). Residues 372 to 401 of the C terminus of NTS1 have been 
shown to be involved in coupling to Gs- and Gi-mediated pathways 
(27), and deletion of residues 374 to 389 was deleterious to G protein 
activation in an NTS1-Gi1/q fusion protein (28). Changes in the local 
dynamics of H8 may be required for receptor signaling, e.g., facili-
tating engagement with G protein and/or arrestin. TM7/H8 con-
formation and/or dynamics were previously shown to be particularly 
sensitive to arrestin-biased ligands for, e.g., the vasopressin receptor 2 
and the  opioid receptor (8, 24). The finger loop of arrestin was also 
shown to interact predominantly with the N-terminal part of H8 of 
opsin (the retinal-free active conformation of rhodopsin) (22). Dis-
ruption of H8 by insertion of a helix-breaking proline at position V379 
resulted in increased binding of ß-arrestin-1 relative to WT receptor 
(Fig. 5), suggesting that structural integrity or dynamics of H8 may 
also play a role in NTS1-arrestin interactions. High local mobility of 
H8 has previously been shown to be required for initial (low-affinity) 
binding of β-arrestin-1 to rhodopsin (12), while deletion or severe 
disruption of H8 by replacing the central K8.53 with a helix-breaking 
proline was reported to perturb the interaction of the bradykinin 
B2 receptor with GPCR kinase 2/3 (GRK 2/3) and ß-arrestin-2 (6). 
Thus, while the presence of H8 appears to be required, structural 
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Fig. 5. Association of NTS1 with -arrestin-1 and extracellular signal-regulated 
kinases 1 and 2 phosphorylation. (A and B) Pull-down assays were performed 
to assess the interaction of -arrestin-1 (Arr1) with the receptor. Specifically, 
HEK293 cells expressing wild-type NTS1 (WT), NTS1-V379P (V379P), or NTS1-V379L 
(V379L) receptors were stimulated with 100 nM NT for 15 min at 37°C. After stim-
ulation, cell lysates were precipitated with anti–hemagglutinin (HA) antibody, and 
Western blotting was performed to probe the amount of -arrestin-1 interacting with 
the receptors. Signals were quantified by densitometry, and values were normalized 
by the amount of -arrestin-1 interacting with NTS1. Each point represents the 
mean of four independent experiments, and error bars represent the SEM. Statis-
tical significance was determined using one-way analysis of variance (ANOVA) with 
Dunnett’s multiple comparison test; *P < 0.05. IP, immunoprecipitation; IB, immuno-
blot. (C) Kinetics profiles for extracellular signal-regulated kinases 1 and 2 (ERK1/2) 
phosphorylation (pERK) after 100 nM NT stimulation in cells expressing WT or V379P 
are shown. Signals were quantified by densitometry, and pERK values were normal-
ized by total ERK values. Each point represents the mean of three independent 
experiments, and error bars represent the SEM. Statistical significance was tested 
using a two-sample two-tailed t test.
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changes that increase its local dynamics might facilitate arrestin in-
teraction directly, or indirectly, for example, by making the receptor 
C terminus more readily accessible for GRKs, although such a hy-
pothesis would require further testing. While no interaction was ob-
served between the 5 helix of the  subunit of Gs and TM7 or H8 of 
2-adrenergic receptor (2AR), more recent structures of GPCR–G 
protein complexes [reviewed in (29)] of the A2A adenosine receptor 
(with mini Gs),  opioid receptor (with Gi), 5-hydroxytryptamine 1B 
(5-HT1B) receptor (with Go), rhodopsin (with Gi), and hNTS1 (with 
Gi1/q) (26) do show direct contacts of the G protein with the N-terminal 
part of H8 similar to that observed for arrestin, suggesting that 
changes in H8 conform ation, positioning, and/or dynamics may 
play a (receptor- dependent) role in G protein recognition and in 
arrestin coupling.
It is worth noting that EPR spectra of the N-terminal half of 
H8 in rhodopsin recorded in a previous study in n-dodecyl -d- 
maltopyranoside (DDM) micelles (10) show stronger immobilization 
of the spin labels and larger maximal differences in H0−1 (0.1 to 
0.27 versus 0.05) between residue positions compared to NTS1 
here, suggesting that H8 may be more dynamic in NTS1 than in 
rhodopsin. The changes observed in the EPR spectra of rhodopsin 
H8 upon light activation were substantially more pronounced than 
those observed for here NTS1. This may reflect the previously pro-
posed difference in energy landscape for activation for rhodopsin and 
other GPCRs (30); covalent coupling to its inverse agonist precludes 
basal activity in rhodopsin, resulting in a larger change upon activa-
tion. It should also be noted that an absence of large changes in 
CW-EPR does not preclude conformational changes (e.g., rigid 
body movements) occurring in NTS1 upon ligand binding. For ex-
ample, CW-EPR spectra of TM6 of the 2AR show only small spectral 
changes upon addition of ligand, or even a G protein mimetic, which 
were of similar magnitude as those observed here for H8 in apo and 
NT-bound NTS1 (30), even though crystallography and pulsed EPR 
measurements have shown large conformational changes under these 
conditions (22, 29, 30).
Both in vitro experiments and simulations suggested that lipid- 
protein interactions are important for H8 secondary structure in-
tegrity; in the absence of lipids, CD and MD showed that a peptide 
corresponding to H8 was unstructured, while the presence of lipids 
or detergent supported its helical structure. Similar results have pre-
viously been obtained for peptides corresponding to the H8 fragment 
of the CB1 cannabinoid (31) and the 2-adrenergic receptors (32) 
by CD and NMR spectroscopy, where helicities of ~65 and 31%, 
respectively, were found in membrane-mimicking environments, 
similar to the values obtained here by CD (fig. S4A), while the pep-
tides appeared unstructured in water. Furthermore, the H8 peptide 
showed higher helical propensity by CD in the presence of BPL than 
in the presence of only PC lipids (Fig. 2), indicating that specific 
lipid headgroup interactions could contribute to its structure. During 
MD simulations of NTS1 in a BPL bilayer, close interactions were 
observed between H8 and all main components of the BPL bilayer 
(POPC, POPE, POPS, and cholesterol) (Fig. 4 and fig. S8). In vivo, 
PE and PS lipids are largely confined to the inner leaflet of the plasma 
membrane (20), and interaction with these lipids in particular ap-
pears to contribute to the higher stability of H8 in BPL membranes 
relative to POPC membranes; frequent interactions with R3778.51 and 
C3868.60 were observed both with POPE and POPS during simula-
tions of the apo and the NT-bound receptor, respectively. The pres-
ence of a basic residue at position 8.51 is highly conserved in class 
A GPCRs (fig. S1), suggesting that this stabilizing lipid-protein in-
teraction may be of general significance. PE lipids have previously 
been shown to be important for NT binding in vitro (18), which may 
be due to stabilization of the native structure of the receptor. The 
observed increase in contacts between H8 and PS lipids in the NT-
bound state suggests that the agonist-bound conformation is partic-
ularly stabilized by interaction with anionic lipids, which have been 
implicated in promoting NTS1 G protein activity in vitro (33). In 
previous simulations using the structure of the thermostabilized 
NTS1-GW5 construct that was crystallized without a structured H8 
(13) and a WT homology model derived therefrom in POPC bilayers 
(23), a modeled H8 was reported to be unstable. While this discrep-
ancy with our results most likely reflects the difference in starting 
model, the lack of stabilizing interactions with other lipid species 
may also have contributed to the lower H8 stability observed (23).
NTS1 produced in Escherichia coli as used here, and as used to 
produce the 4BUO crystal structure (14), is not posttranslationally 
modified and thus lacks palmitoylation of the C-terminal cysteine 
residues. An MD study of the dopamine D2 receptor embedded in 
lipid raft-like membranes showed that C-terminal palmitoylation 
enhanced membrane penetration by the H8 backbone, while depal-
mitoylation enabled H8 to move out into the aqueous environment 
(34). Our MD simulations suggest that lipid-protein interactions, 
such as the extensive interactions observed between PE and PS lipids 
and C386 of NTS1, may stabilize H8 in the absence of palmitoyla-
tion at this C-terminal cysteine residue (Fig. 4) and maintain partial 
insertion of its C-terminal end into the membrane throughout the 
MD simulation (fig. S5D). Furthermore, the palmitoylation thio-
ester bond is labile, making it a transient posttranslational modifi-
cation. Previous studies of several GPCRs have established that levels 
of receptor palmitoylation can be modulated by, e.g., agonist binding 
[reviewed in (35)], suggesting that this modification is dynamic and 
regulated and that pools of depalmitoylated receptors exist. In hNTS1, 
inhibition of palmitoylation has been linked to reduced interaction 
with Gq and lower levels of ERK1/2 phosphorylation, which was 
ascribed to diminished localization to structured membrane micro-
domains (36). Thus, while palmitoylation of the C-terminal cysteines 
does not appear to be an essential requirement for H8 helicity, it 
might have a stabilizing and regulating effect.
In conclusion, this study confirms the presence of a structured 
H8 in NTS1, both for apo and agonist-bound receptor, which is sta-
bilized by lipid-protein interactions. Whether the fact that H8 was 
only observed in part of the solved crystal structures is due to protein 
engineering, crystallographic conditions, lack of specific lipid-protein 
stabilizing contacts, or inherent flexibility of H8 remains unclear. 
Accumulating evidence suggests that H8 structure, dynamics, and 
conformation may play a role in GPCR signaling and, in particular, 
in arrestin-biased pathways, and the techniques used here could be 
extended to studies in the presence of signaling partners, such as G 
proteins or -arrestins, to shed more light on the structural basis of 
the activation mechanisms of different GPCR signaling pathways 
and the role that lipids play therein.
MATERIALS AND METHODS
NTS1 purification, spin labeling, and reconstitution
The rat NTS1 was produced as a fusion construct, NTS1BH6 (MBP-
TEV-rT43NTS1-His6-TEV-TrxA-His10), where NTS1 is truncated 
at the N terminus (1 to 42), has a His6 tag added to its C terminus 
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and is flanked by tobacco etch virus (TEV) protease recognition sites 
separating it from its N- and C-terminal fusion partners, maltose- 
binding protein, and thioredoxin, followed by an additional C- 
terminal His10 tag, respectively (17). Sequential single-cysteine 
mutations (for residues 374 to 393) were introduced in a cysteine- 
depleted background mutant of NTS1BH6 (C172S3.55, C278SIC3, 
C332S6.59, C386SC-term, and C388AC-term, where superscripts refer to 
the Ballosteros-Weinstein numbering), previously described in (17). 
Cysteine mutants of NTS1BH6 were expressed in E. coli BL21(DE3), 
purified, and reconstituted as previously described (17). Briefly, 
NTS1BH6 was solubilized from E. coli cell pellet in 50 mM tris-HCl 
(pH 7.4), 200 mM NaCl, 30% glycerol (v/v), 1% DDM (w/v), 0.5% 
CHAPS (w/v), and 0.1% (w/v) cholesteryl hemisuccinate (CHS), 
supplemented with protease inhibitors [leupeptin (2 g/ml), pep-
statin A (2 g/ml), and aprotinin (3 g/ml)]. NTS1BH6 was purified 
from clarified lysate by immobilized metal affinity chromatography 
[eluting in 50 mM tris-HCl (pH 7.4), 200 mM NaCl, 10% glycerol 
(v/v), 0.5% CHAPS (w/v), 0.1% DDM (w/v), 0.1% CHS (w/v), and 
500 mM imidazole], after which fusion partners were removed by 
proteolytic cleavage with TEV protease. The receptor was diluted 
with salt-free buffer to reduce the NaCl (<70 mM) concentration 
and further purified by ligand-affinity chromatography using N- 
terminally Cys-derived NT (Alta Bioscience) immobilized on UltraLink 
Iodoacetyl Resin (Pierce, Thermo Fisher Scientific), ensuring that the 
final sample contained only properly folded receptor, capable of li-
gand binding. The sample was incubated with the resin for at least 
2 to 3 hours at 4°C, and impurities were removed by washes with 
70 and 150 mM NaCl [50 mM tris-HCl (pH 7.4), 10% glycerol 
(v/v), 0.1% DDM (w/v), and 0.01% CHS (w/v)], after which NTS1 
was eluted with 1 M NaCl. The NT column eluate was incubated 
with 10 mM dithiothreitol (DTT) for 2 to 3 hours at 4°C and con-
centrated by loading it on a 1-ml HisTrap Ni2+ column, extensively 
washing (~50 to 90 column volumes) to remove DTT and eluting 
with 400 mM imidazole. Eluted receptor was then incubated with a 
20-fold molar excess of MTSL (Toronto Research Chemicals) spin 
label over receptor for 45 min at room temperature, after which 
the sample was buffer- exchanged, and excess label was removed by 
gel filtration using two 5-ml HiTrap Desalting columns (GE Healthcare) 
connected in series and equilibrated with 50 mM tris-HCl (pH 7.4), 
50 mM NaCl, 10% glycerol (v/v), 0.1% DDM (w/v), 0.01% CHS 
(w/v), and 1 mM EDTA. The labeled receptor was then reconsti-
tuted into 100-nm extruded porcine BPL (Avanti Polar Lipids) li-
posomes at an initial lipid-to-protein molar ratio of 1750:1 using 
Bio-Beads SM-2 Resin (Bio-Rad) for detergent removal. Proteolipo-
somes (containing ~1.5 to 3 nmol of NTS1) were resuspended in 10 l 
of liposome buffer [50 mM tris-HCl, 50 mM NaCl, 10% glycerol 
(v/v), and 1 mM EDTA (pH 7.4)], with or without a 5- to 10-fold mo-
lar excess of agonist, NT8–13 (Sigma- Aldrich), the active C-terminal 
fragment of NT. Two biological replicates were prepared for each 
label position.
CW-EPR on NTS1
Samples were loaded into ~0.5-mm glass capillaries (Sigma-Aldrich), 
which were flame-sealed at one end before loading. Spectra were 
recorded on an X-band CW spectrometer (EMX, Bruker). The tem-
perature was controlled (295 or 170 K) using a nitrogen cryostat 
coupled to a variable temperature unit (Oxford Instruments). Spectra 
were typically collected with a sweep width of 200 G, at 45 s per 
scan, and the time constant was adjusted to ~10% of the conversion 
time. The modulation amplitude was set to 1 or 3 G for spectra re-
corded at 295 or 170 K, respectively. Receiver gain was set at 40 to 
60 dB, and microwave power was adjusted to avoid saturation (10 mW 
at 295 K and 0.1 mW at 170 K). Between 10 and 20 scans (recording 
time ~ 8 to 15 min) were collected and averaged. Single spectra that 
were recorded as a control before and after the recording of an 
averaged spectrum, to verify the stability of the receptor over the 
course of the measurements, were indistinguishable. Spectra were 
normalized to the integrated intensity of the absorption spectra. 
Rotational correlation times (c) were estimated from the maximum 
outer splitting 2Azz′ of the spectra recorded at 295 K (see fig. S2) 
using the method of Freed (21), where the maximum outer splitting 
of the spectra recorded at 170 K was used to determine the rigid 
limit 2AzzR. To determine H0, spectra were smoothened using cubic 
splines in R (using RStudio) and interpolated, and the global maxima 
and minima were extracted. Nelder-Mead optimization in R was 
subsequently used to fit sine functions to (H0)−1 (average of the 
two biological repeats) plotted against residue number (374 to 393) 
for all possible residue stretches, discarding results for stretches 
shorter than four residues. Results were ranked according to the 
resulting residual sum of squares.
CW-EPR with spin-labeled lipids
POPC and 5/12/14-PCSL or DOXYL-PC were purchased from Avanti 
Polar Lipids (Alabaster, AL, USA). Lipids were dissolved in chloroform 
to give stocks (25 mg/ml) and stored at −20°C. A peptide correspond-
ing to S373-C388 of NTS1 (H8 peptide: Ac-SANFRQVFLSTLACLC- 
NH2) was purchased from Peptide Synthetics and used without 
further purification. LUVs were formed with a spin label installed 
in the outer leaflet of the membrane; for the inner leaflet, the lipid 
compositions of the donor and acceptor vesicles are reversed. Spe-
cifically, adapting a protocol from Cheng et al. (20), donor multi-
lamellar vesicles (MLVs) were prepared by mixing POPC (12 mg, 
16 mol) and DOXYL-PC (0.24 mg, 0.3 mol) in CHCl3 and dried 
under nitrogen and then in vacuo for 1 hour. The dried lipid film 
was suspended in H2O (500 l) to a concentration of 32 M and left 
to stand at 40°C for 1 hour, with occasional, gentle vortexing. The 
MLVs were then incubated with 500 l of methyl--cyclodextrin 
(MCD; Sigma-Aldrich, 64 mol) for 2 hours at 1000 rpm and 
50°C using a heated vortexer (Eppendorf Thermomixer Comfort). 
At the same time, acceptor LUVs were formed by first preparing 
MLVs of POPC (3 mg, 4 mol) in H2O with 20% (w/v) sucrose 
(500 l) and then subjected to five freeze-thaw cycles between liquid 
N2 and 40°C. The freeze-thawed MLVs were extruded 11 times 
through 100-nm polycarbonate filters (Avanti Polar Lipids). The 
sucrose- entrapped vesicles were diluted with H2O (9 ml) and cen-
trifuged for 2 hours at 190,000g and 40°C, using a Beckman Optima 
XL-100 K Ultracentrifuge and SW 41 Ti rotor. The pelleted vesicles 
were then resuspended in H2O (500 l) to a final concentration of 
8 M. The sucrose-entrapped LUVs were added to the solution of 
MCD- solubilized MLVs, and the resulting suspension was mixed 
for 30 min at 1000 rpm and 50°C using a heated vortexer. This mixed 
suspension was then diluted in 9 ml of 4.5% (w/v) sucrose solution 
and centrifuged for 2 hours at 190,000g and 10°C. The unpelleted 
MLVs and MCD were removed in the supernatant, and the ex-
change LUVs were resuspended in 50 mM phosphate buffer (pH 7.2; 
100 l). H8 peptide in dimethyl sulfoxide (DMSO) was added to 
give a peptide-to-lipid (P:L) molar ratio of 1:25. The relative con-
centrations of inner leaflet– and outer leaflet–labeled vesicles were 
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calculated using fluorescence of 0.1% Rhodamine PE in the accep-
tor vesicles to ensure that the P:L ratio was the same. An identical 
volume of DMSO was added to lipid-only samples. The mixed sus-
pension was then diluted in 9 ml of 4.5% (w/v) sucrose solution and 
centrifuged for 2 hours at 190,000g and 10°C. CW-EPR measurements 
were carried out at 293 K on an X-band CW spectrometer (EMX, 
Bruker) fitted with a nitrogen cryostat. The hyperfine splittings Apar 
and Aper were obtained from the EPR spectra, and the apparent or-
der parameter Sapp was calculated according to the equation
  S app =  
 A par +  A per*    ─   
 A zz −  
   A xx −  A yy 
 
 _ 
  2
  
        * a ' 0  ─ a 0  
where Azz, Ayy, and Axx are the principal hyperfine splittings 
(32.9, 5.4, and 5.9 for DOXYL, respectively) of the molecular axes 
of the spin label
  a ' 0  ─ a 0  =  
 A zz +  A xx +  A yy   ─ A par +  A per*  
is a normalization term for the polarity of the environment, and
  A per* =  A per +  ( 1.4 *  [  1 −  ( A par −  A per   ─  A zz −   A xx +  A yy     _ 2  
  ] ) 
accounts for dependence of the hyperfine splittings (Aper) on the 
local polarity (21).
Circular dichroism
For CD measurements, the H8 peptide was dissolved at 15 mg/ml in 
trifluorethanol (TFE) and then diluted to 0.1 mg/ml in (i) 20 mM 
sodium phosphate, 20 mM NaCl buffer, or buffer containing either 
(ii) POPC liposomes (0.43 mg/ml), (iii) BPL liposomes (0.37 mg/ml) to 
a 5:1 lipid-to-peptide molar ratio, (iv) 1% octyl -d glucoside, 0.01% 
CHS, or (v) 0.1% DDM, 0.01% CHS (w/v). Peptide concentration was 
measured using absorption at 205 nm. Liposomes were prepared by 
extrusion through 100-nm polycarbonate filters (Whatman). CD 
spectra were recorded at 293 K between 190 and 260 nm on a Jasco 
J-815 Spectropolarimeter using a 1-mm quartz cuvette, a scan rate 
of 20 nm/min, and a data integration time of 1 s. The recorded spectra 
were corrected for buffer contribution, accounting for TFE (0.67%) 
and the appropriate lipid/detergent. The data were smoothed in 
OriginPro 8.5 (OriginLab) using Savitzky-Golay filtering (10-nm 
window, second-order polynomial), and the DichroWeb server was 
used to estimate secondary structure; results from multiple algorithms 
(K2D, CONTIN, CDSSTR, and SELCON3) and reference datasets 
(sets 4, 7, SP175, and SMP180) that gave a normalized RMSD below 
0.1 were averaged.
MD simulations
The NTS1 crystal structure of highest resolution containing a re-
solved H8 (PDB code 4BUO) (14) was used as initial conformation 
(upon ligand removal), and the non-resolved IC1 was modeled with the 
software MODELLER [the model with the best Discrete Optimized 
Protein Energy (DOPE) score was chosen]. For the simulations of the 
H8 peptides and NTS1 comparing POPC and BPL, simulations were 
run using GROMACS (v. 4.6.3). Self-assembly coarse-grained (CG)–
MD simulations (37) in a POPC membrane were first performed for 
100 ns at 323 K using the MARTINI force field, giving a membrane- 
embedded protein with about 300 POPC lipids, solvated with water 
particles and ~150 mM NaCl. The final systems were then converted 
to atomistic detail using the CG2AT protocol, then bilayer/solvent- 
equilibrated (with positional restraints on the protein) for 1 ns, and lastly 
run for a further 200 ns (at 310 K) of AT-MD with the GROMOS96 
53a6 force field. The self-assembled POPC CG systems were lipid- 
exchanged (38) to build the BPL-like membrane models, composed 
of POPC:POPS: POPE:cholesterol at a ratio of 15:22:39:24, therefore 
mimicking the composition of BPL extract. The resulting heteroge-
neous membrane systems were submitted, before conversion back 
to atomistic, to a 100-ns CG-MD simulation at 323 K using the same 
parameters as for the POPC CG-MD. Each atomistic system was con-
sidered to be in equilibrium after the first 20 ns of AT-MD, based on 
NTS1 backbone RMSD. Therefore, the trajectory analysis was per-
formed from 20 to 200 ns for each AT-MD simulation, using the 
GROMACS and VMD tools. Further triplicate simulations were run 
using apo WT NTS1, NT-bound WT NTS1, and apo mutant NTS1 
where Tyr369 is mutated to Ala (Y7.53A), in a BPL-like bilayer as de-
scribed above with a few differences. Specifically, simulations were run 
using GROMACS (v.2019), the CHARMM36 force field was used for 
the AT-MD simulations, and Insane (39) was used to build the BPL-
like membrane models (same lipid ratio as in the other simulations); 
the resulting heterogeneous membrane systems were submitted to a 
500-ns CG-MD simulation at 310 K, before conversion back to at-
omistic. Atomistic simulations of 200 ns were performed in tripli-
cate. Lipid-protein contacts (≤3.5 Å) per lipid species observed during 
MD simulations were quantified for each condition for the timeframe 
in equilibrium (20 to 200 ns). The number of contacts was normalized 
by the total number of interactions during each simulation run and 
subsequently weighted by the percentage of each lipid type found 
in the mixed bilayer. Averages from the triplicate runs were calcu-
lated and subjected to statistical analysis using R (in RStudio) using 
a Bayesian alternative to the two-sample t test, BEST (40).
Pull-down assays
Rat NTS1 receptor was cloned into the pOPINHA vector (a gift from 
R. Owens, OPPF-UK) using the InFusion cloning method (Clontech). 
The vector containing the receptor was used as the template to gen-
erate V379P and V379L mutants using QuikChange (Stratagene) 
according to the manufacturer’s instructions. The sequence of each 
construct was confirmed by DNA sequencing.
HEK293T cells were cultivated in Dulbecco’s modified Eagle’s 
medium (DMEM; Sigma-Aldrich) supplemented with 10% (v/v) fetal 
bovine serum and glutamine (2 mM) in a 5% CO2 environment at 
37°C. NTS1, NTS1-V379P, and NTS1-V379L plasmids were tran-
siently transfected into HEK293T cells using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s instructions. Thirty-six hours 
after the transfection, cells were serum-starved overnight. Subse-
quently, cells were stimulated with 100 nM NT (Sigma-Aldrich) 
during 15 min. Following stimulation, cells were placed on ice, washed 
with phosphate-buffered saline buffer and lysed with 1 ml of cold buffer 
[50 mM tris-HCl (pH 7.5), 150 mM NaCl, 1% Nonidet P-40, apro-
tinin (100 g/ml), leupeptin (10 g/ml), 1 mM sodium ortovanadate, 
and 10 mM sodium fluoride). After lysis by douncing (20 strokes), 
the lysates were centrifuged at 4°C, 10,000g for 15 min. The super-
natants were incubated with 2 g of anti-hemagglutinin (HA) anti-
body (Sigma-Aldrich) for 1 hour at 4°C with agitation. After this 
period of incubation, 20 l of precleared protein A/G agarose beads 
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(Santa Cruz Biotechnology) was added, and samples were rotated 
for 1 hour at 4°C. Subsequently, beads were centrifuged and washed 
three times with lysis buffer, and bound proteins were eluted by 
heating to 85°C with 40 l of 2X SDS–polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer. A/G agarose beads were 
pelleted, the eluted supernatants were separated by SDS-PAGE and 
transferred to nitrocellulose membranes, and Western blotting was 
performed against -arrestin-1 (1:1000, BD Biosciences) and the 
receptor (anti-HA, 1:1000, Sigma-Aldrich). Densitometric values were 
obtained using ImageJ (https://imagej.nih.gov/ij/), and correspond-
ing results were plotted using GraphPad (GraphPad Software Inc.). 
Statistical significance was determined using one-way analysis of 
variance (ANOVA) with Dunnett’s multiple comparison test using 
GraphPad Prism. A P value of <0.05 was considered statistically 
significant.
ERK1/2 phosphorylation assays
HEK293T cells were cultivated in DMEM (Sigma-Aldrich) with 
10% (v/v) fetal bovine serum and glutamine (2 mM) in a 5% CO2 
environment at 37°C. NTS1 and NTS1-V379P plasmids were tran-
siently transfected into cells using Lipofectamine 2000 (Invitrogen) 
following the manufacturer’s instructions. Twenty-four hours after 
transfection, 3.0 × 105 transfected cells were seeded on six-well plates 
in DMEM supplemented with 10% (v/v) serum fetal bovine and 
glutamine (2 mM) and maintained in a 5% CO2 environment at 37°C 
during 12 hours. Subsequently, cells were serum-starved overnight 
and then stimulated with 100 nM NT for the indicated period of 
time (0 to 30 min) and analyzed for ERK phosphorylation. After NT 
stimulation, cells were lysed with lysis buffer consisting of 50 mM 
tris-HCl (pH 7.4), 150 mM NaCl, 1% Nonidet P-40, and protease 
inhibitors [leupeptin (10 g/ml), aprotinin (100 g/ml), 1 mM sodium 
orthovanadate, and 10 mM sodium fluoride]. Following homog-
enization at 4°C during 30 min, cellular lysate was centrifuged at 
4°C, 13,000g for 15 min, and total protein was quantified by bi-
cinchonic acid (BCA) assay (Thermo Fisher Scientific). After that, 
30 g of total protein was separated by SDS-PAGE and transferred 
to nitrocellulose membrane, and Western blotting was performed 
against total ERK and phosphorylated ERK (pERK, both antibodies 
from Cell Signaling Technology). Densitometric values obtained 
with ImageJ (https://imagej.nih.gov/ij/) were used to calculate the 
ratio of pERK to total ERK, and corresponding results were plotted 
using GraphPad (GraphPad Software Inc.). Statistical significance was 
tested using a two-sample two-tailed t test using GraphPad Prism.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/33/eaav8207/DC1
View/request a protocol for this paper from Bio-protocol.
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